Evidence map›Paper›PMID 40136372›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Evaluation of Clinical Parameters Associated with Response and Resistance to Cemiplimab in Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma: A Multi-Institutional Retrospective Cohort Study.

Joseph Edward Haigh, Sam Rack, Ruiyang Yan, Sherin Babu, Olly Donnelly, Harriet Walter, Guy Faust, Shradha Bhagani, Patrick Isola, Robert Metcalf

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joseph Edward HaighThe Christie NHS Foundation Trust, Wilmslow Road Manchester, Manchester M20 4BX, UK.ORCID 0009-0001-6389-6276
Sam RackThe Christie NHS Foundation Trust, Wilmslow Road Manchester, Manchester M20 4BX, UK.
Ruiyang YanThe Christie NHS Foundation Trust, Wilmslow Road Manchester, Manchester M20 4BX, UK.ORCID 0000-0003-1431-7271
Sherin BabuThe Christie NHS Foundation Trust, Wilmslow Road Manchester, Manchester M20 4BX, UK.
Olly DonnellyPortsmouth Hospitals University NHS Trust, Southwick Hill Road, Cosham PO6 3LY, UK.ORCID 0000-0001-8613-6686
Harriet WalterUniversity Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK.
Guy FaustUniversity Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK.
Shradha BhaganiUniversity Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK.ORCID 0000-0001-7251-2249
Patrick IsolaPortsmouth Hospitals University NHS Trust, Southwick Hill Road, Cosham PO6 3LY, UK.
Robert MetcalfThe Christie NHS Foundation Trust, Wilmslow Road Manchester, Manchester M20 4BX, UK.

Funding

Syncona Foundation No applicable grant numberThe Christie Charity No applicable grant numberThe Infrastructure Industry Foundation No applicable grant number
6 · The paper itself

Abstract

Cutaneous squamous cell carcinoma (cSCC) is a common cancer with increasing incidence and 5% of patients develop incurable disease, often resistant to chemotherapy. The anti-PD-1 therapy cemiplimab has shown high efficacy in clinical trials. This retrospective study evaluated the real-world effectiveness of cemiplimab in incurable cSCC and examined factors influencing response and toxicity. Data from 86 patients across three UK healthcare providers were analysed. Median progression-free survival (PFS) and overall survival (OS) were not reached, with 38% showing durable responses beyond 12 months. The overall response rate was 60.8% (95% CI 49-71), and the clinical benefit rate was 74.3% (95% CI 63-83). A head and neck primary site was associated with improved PFS (

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCarcinoma, Squamous CellSkin NeoplasmsAdultAgedAged, 80 and overDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedNeoplasm MetastasisRetrospective StudiesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalcemiplimabcemiplimabcutaneous squamous cell carcinomaprimary site

Identifiers

PMID40136372
PMCPMC11941019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.